SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00903292

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma

Currently the investigators have two different classes of second-line treatment options in recurrent non-small Cell Lung Cancer (NSCLC). In chemotherapy, docetaxel and pemetrexed produced similar treatment efficacy outcomes, while pemetrexed had a better tolerability. In recent analysis of pemetrexed clinical studies, a strong treatment-by-histology interaction in overall survival and progression free survival that indicated better efficacy for non-squamous patients treated with pemetrexed. These data supports that pemetrexed could be a preferable chemotherapy drug especially in adenocarcinoma NSCLC patients.

NCT00903292 Non-Small Cell Lung Cancer
MeSH:Adenocarcinoma Adenocarcinoma of Lung

2 Interventions

Name: erlotinib (Tarceva)

Description: chemotherapy with erlotinib
Type: Drug
Group Labels: 1

A, erlotinib

Name: pemetrexed (Alimta)

Description: Chemotherapy with pemetrexed
Type: Drug
Group Labels: 1

B, pemetrexed


Primary Outcomes

Measure: The primary analysis will be the overall best response rate, including a 95% confidence interval (Leemis and Trivedi 1996).

Time: 02/2009 - 04/2010

Purpose: Screening

Parallel Assignment


There is one SNP

SNPs


1 L858R

Since typical EGFR gene mutations (i.e., the deletion of typically five amino acids at codons 746-750 (ELREA) in exon 19 and a leucine-to-arginine mutation at codon 858 (L858R)) are a good predictor for tumor response to tyrosine kinase inhibitor, this present study is to tailor the patient's treatment according to his/her EGFR gene mutation status. --- L858R ---



HPO Nodes